Real-world utilization pattern of dydrogesterone in 7287 Indian women with obstetric and gynecological conditions: data from multicentric, retrospective study.

Jaydeep Tank, Sanjay Gupte, Purna Chandra Mahapatra, Jayanthi Reddy, Pratima Mittal, Ashish Kumar Mukhopadhyay, Lila Vyas, Achla Batra, Mahesh Gupta, Sunita Tandulwadkar, Sunita Chandra, Vidya Bhat, Kawita Bapat, Parikshit Tank, Ketan Kulkarni, Onkar Swami
{"title":"Real-world utilization pattern of dydrogesterone in 7287 Indian women with obstetric and gynecological conditions: data from multicentric, retrospective study.","authors":"Jaydeep Tank, Sanjay Gupte, Purna Chandra Mahapatra, Jayanthi Reddy, Pratima Mittal, Ashish Kumar Mukhopadhyay, Lila Vyas, Achla Batra, Mahesh Gupta, Sunita Tandulwadkar, Sunita Chandra, Vidya Bhat, Kawita Bapat, Parikshit Tank, Ketan Kulkarni, Onkar Swami","doi":"10.61622/rbgo/2024AO18","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Despite the literature on dydrogesterone, studies on dydrogesterone utilization patterns are largely lacking in Indian patients.</p><p><strong>Methods: </strong>This was a multi-center, retrospective, observational, cross-sectional, and descriptive study across 817 centers in India. Data of patients who received dydrogesterone in past and provided consent for future use of their medical record for research purpose was were retrieved and analyzed.</p><p><strong>Results: </strong>Data of 7287 subjects (aged 29.55±4.84 years) was analyzed. Threatened abortion was the most common indication for which the subjects received dydrogesterone (46.9%) followed by recurrent pregnancy loss. Polycystic ovary syndrome (PCOS), thyroid disorders and anemia were the most common comorbid conditions and prior pregnancy loss, advanced maternal age and obesity were the most common risk factors seen in subjects who received dydrogesterone. Total 27.5% of subjects received a loading dose of dydrogesterone, and majority (64%) received 40 mg as loading dose. 10 mg dose was used as maintenance or regular dose in 81.4% of the subjects. Twice daily (BID) was the most common dosing frequency (66.6%). The most common concomitant medications being taken by the subjects on dydrogesterone included folic acid (45.1%), iron supplements (30.3%) and calcium and vitamin D3 supplements (25.5%). Another progesterone preparation (oral, injection, vaginal, tubal) other than dydrogesterone was used concurrently in 7.8% of subjects.</p><p><strong>Conclusion: </strong>The study helped to identify the patient population that is benefitted by dydrogesterone and the preferred indications, risk factors, comorbid conditions and concomitant medication used in this patient population at real-life scenario.</p>","PeriodicalId":74699,"journal":{"name":"Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11075425/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.61622/rbgo/2024AO18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Despite the literature on dydrogesterone, studies on dydrogesterone utilization patterns are largely lacking in Indian patients.

Methods: This was a multi-center, retrospective, observational, cross-sectional, and descriptive study across 817 centers in India. Data of patients who received dydrogesterone in past and provided consent for future use of their medical record for research purpose was were retrieved and analyzed.

Results: Data of 7287 subjects (aged 29.55±4.84 years) was analyzed. Threatened abortion was the most common indication for which the subjects received dydrogesterone (46.9%) followed by recurrent pregnancy loss. Polycystic ovary syndrome (PCOS), thyroid disorders and anemia were the most common comorbid conditions and prior pregnancy loss, advanced maternal age and obesity were the most common risk factors seen in subjects who received dydrogesterone. Total 27.5% of subjects received a loading dose of dydrogesterone, and majority (64%) received 40 mg as loading dose. 10 mg dose was used as maintenance or regular dose in 81.4% of the subjects. Twice daily (BID) was the most common dosing frequency (66.6%). The most common concomitant medications being taken by the subjects on dydrogesterone included folic acid (45.1%), iron supplements (30.3%) and calcium and vitamin D3 supplements (25.5%). Another progesterone preparation (oral, injection, vaginal, tubal) other than dydrogesterone was used concurrently in 7.8% of subjects.

Conclusion: The study helped to identify the patient population that is benefitted by dydrogesterone and the preferred indications, risk factors, comorbid conditions and concomitant medication used in this patient population at real-life scenario.

7287 名患有妇产科疾病的印度妇女使用地屈孕酮的实际情况:多中心回顾性研究数据。
摘要尽管有关地屈孕酮的文献很多,但有关印度患者使用地屈孕酮模式的研究却非常缺乏:这是一项涉及印度 817 个中心的多中心、回顾性、观察性、横断面和描述性研究。检索并分析了过去接受过地屈孕酮治疗并同意将来将其病历用于研究目的的患者数据:结果:分析了 7287 名受试者(年龄为 29.55±4.84 岁)的数据。受试者服用地屈孕酮最常见的原因是妊娠流产(46.9%),其次是反复妊娠流产。多囊卵巢综合征(PCOS)、甲状腺疾病和贫血是最常见的并发症,而之前的妊娠失败、高龄产妇和肥胖是接受地屈孕酮治疗的受试者最常见的风险因素。共有 27.5%的受试者接受了地屈孕酮的负荷剂量,其中大多数(64%)接受了 40 毫克的负荷剂量。81.4%的受试者将 10 毫克作为维持剂量或常规剂量。每天两次(BID)是最常见的给药频率(66.6%)。服用地屈孕酮的受试者最常同时服用的药物包括叶酸(45.1%)、铁补充剂(30.3%)以及钙和维生素 D3 补充剂(25.5%)。7.8%的受试者同时使用了除地屈孕酮以外的另一种孕酮制剂(口服、注射、阴道、输卵管):这项研究有助于确定地屈孕酮的受益患者人群,以及在现实生活中该患者人群的首选适应症、风险因素、合并症和同时使用的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信